Author:
Brainard Diana M.,McHutchison John G.
Publisher
Springer International Publishing
Reference11 articles.
1. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 61:S45–S57
2. Lawitz E, Freilich B, Link J et al (2015) A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 22:1011–1019
3. Everson GT, Towner WJ, Davis MN et al (2015) Sofosbuvir with velpatasvir in treatment-naïve noncirrhotic patients with genotype 1 to 6 hepatitis C virus infection: a randomized trial. Ann Intern Med 163:818–826
4. Gane EJ, Hyland RH, An D, McNally J, Brainard DM, Symonds WT, McHutchison JG, Stedman DA (2014) Once daily sofosbuvir with GS-5816 for 8 weeks with or without ribavirin in patients with HCV genotype 3 without cirrhosis result in high rates of SVR12: the ELECTRON2 study. Hepatology 60(4 (suppl)):236A
5. Pianko S, Flamm SL, Shiffman ML et al (2015) Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med 163:809–817
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献